https://www.selleckchem.com/pr....oducts/Azacitidine(V
3%; 2-year survival rates of 62.9%, 24.7%, and 9.0%; 3-year survival rates of 34.7%, 4.0%, and 0%; and median survival of 21.7 months, 13.6 months, and 8.7 months, respectively. The radical resection group had the longest overall survival (P less then 0.001). Treatment method, albumin (AL, total bilirubin (TBIL), postoperative pathological T-stage, and distant metastasis were identified as independent prognostic indicators of survival. Conclusions Radical resection significantly increases survival in patients with HCCA, an